Literature DB >> 23993721

Retropupillary Artisan intraocular lens implantation in very young children with aphakia following penetrating eye injuries.

Kanmin Xue1, Göran Darius Hildebrand.   

Abstract

Visual rehabilitation of children with penetrating eye injuries often carries a poor prognosis. When capsular support is insufficient, implantation of the aphakic Artisan (Ophtec, The Netherlands) iris-claw intraocular lens (IOL) in front of the iris is an accepted alternative to anterior chamber or scleral-fixated implantation. With anterior chamber lens implantation, however, there is concern about long-term endothelial loss. Posterior iris (or retropupillary) fixation of an Artisan IOL theoretically reduces this risk. We present three consecutive cases of penetrating eye injury resulting in aphakia successfully repaired by retropupillary implantation of the Artisan IOL. The patients achieved best-corrected visual acuities of 20/25 to 20/30 (0.10-0.15 logarithm of the minimum angle of resolution) at 8, 13, and 22 months' follow-up, respectively.
Copyright © 2013 American Association for Pediatric Ophthalmology and Strabismus. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23993721     DOI: 10.1016/j.jaapos.2013.03.021

Source DB:  PubMed          Journal:  J AAPOS        ISSN: 1091-8531            Impact factor:   1.220


  3 in total

1.  Experience of early implantation of retropupillary iris-claw intraocular lens in childhood.

Authors:  Göran Darius Hildebrand; Kanmin Xue
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-04-28       Impact factor: 3.117

Review 2.  Calculation of iris-claw IOL power for correction of late in-the-bag IOL complex dislocation.

Authors:  Valentín Huerva; Francisco J Ascaso; Isabel Caral; Andrzej Grzybowski
Journal:  BMC Ophthalmol       Date:  2017-07-11       Impact factor: 2.209

Review 3.  Surgical Management of Paediatric Aphakia in the Absence of Sufficient Capsular Support.

Authors:  Evdoxia-Maria Karasavvidou; Craig Wilde; Anwar Zaman; Gavin Orr; Dharmalingam Kumudhan; Georgios D Panos
Journal:  J Ophthalmol       Date:  2021-12-04       Impact factor: 1.909

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.